Antiplatelet resistance with aspirin and clopidogrel: Is it real and does it matter?

Current Cardiology Reports

Volumn 8, Issue 4, 2006, Pages 301-306

  Chen, Wai Hong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; HIRULOG; PLACEBO; TICLOPIDINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; FOLLOW UP; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; ISCHEMIA; MONOTHERAPY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; REVIEW; STROKE; THROMBOCYTE; TREATMENT OUTCOME;

ASPIRIN; CORONARY ARTERIOSCLEROSIS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; TICLOPIDINE;

EID: 33745885912     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-006-0063-5     Document Type: Review

References (43)

1. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
2. Barnathan ES, Schwartz JS, Taylor L, et al.: Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987, 76:125-134.
3. Schwartz L, Bourassa MG, Lesperance J, et al.: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988, 318:1714-1719.
4. Lembo NJ, Black AJR, Roubin GS, et al.: Effect of pre-treatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990, 65:422-426.
5. Patrono C, Bachmann F, Baigent C, et al.: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004, 25:166-181.
6. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339.
7. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
8. Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
9. Sabatine MS, Cannon CP, Gibson CM, et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179-1189.
10. Chen ZM, Pan HC, Chen YP, et al.: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621.
11. Mehta J, Mehta P, Burger C, Pepine CJ: Platelet aggregation studies in coronary artery disease. Part 4. Effect of aspirin. Atherosclerosis 1978, 31:169-175.
12. Grotemeyer KH: Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991, 63:587-593.
13. Pappas JM, Westengard JC, Bull BS: Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 1994, 118:801-804.
14. Buchanan MR, Brister SJ: Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995, 11:221-227.
15. Mueller MR, Salat A, Stangl P, et al.: Variable platelet response to low-dose aspirin and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997, 78:1003-1007.
16. Hurlen M, Seljeflot I, Arnesen H: The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J 1998, 32:233-237.
17. Gum PA, Kottke-Marchant K, Poggio ED, et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001, 88:230-235.
18. Andersen K, Hurlen M, Arnesen H, Seljeflot I: Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002, 108:37-42.
19. Macchi L, Christiaens L, Brabant S, et al.: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002, 107:45-49.
20. Grundmann K, Jaschonek K, Kleine B, et al.: Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003, 250:63-66.
21. Wang JC, Aucoin-Barry D, Manuelian D, et al.: Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003, 92:1492-1494.
22. Lee PY, Chen WH, Ng W, et al.: Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005, 118:723-727.
23. McKee SA, Sane DC, Deliargyris EN: Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002, 88:711-715.
24. Bhatt DL: Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004, 43:1127-1129.
25. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients. Thromb Res 1993, 71:397-403.
26. Eikelboom JW, Hirsh J, Weitz JI, et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655.
27. Gum PA, Kottke-Marchant K, Welsh PA, et al.: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
28. Chen WH, Lee PY, Ng W, et al.: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004, 43:1122-1126.
29. Chen WH, Lee PY, Ng W, et al.: Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2005, 96:760-763.
30. Jaremo P, Lindahl TL, Fransson SG, Richter A: Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002, 252:233-238.
31. Gurbel PA, Bliden KP: Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003, 91:1123-1125.
32. Muller I, Besta F, Schulz C, et al.: Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003, 89:783-787.
33. Soffer D, Moussa I, Harjai KJ, et al.: Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003, 59:21-25.
34. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
35. Mobley JE, Bresee SJ, Wortham DC, et al.: Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004, 93:456-458.
36. Serebruany VL, Steinhubl SR, Berger PB, et al.: Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246-251.
37. Wiviott SD, Antman EM: Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004, 109:3064-3067.
38. Nguyen TA, Diodati JG, Pharand C: Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005, 45:1157-1164.
39. Barragan P, Bouvier JL, Roquebert PO, et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003, 59:295-302.
40. Matetzky S, Shenkman B, Guetta V, et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
41. Lev EI, Patel RT, Maresh KJ, et al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006, 47:27-33.
42. Bhatt DL, Topol EJ: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004, 148:263-268.
43. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H: Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (Aspirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004, 38:353-356.